📌 #HeartFailure with Preserved Ejection Fraction in the #Elderly

#Review #HFpEF #aging

🔥RV contractile reserve matters!
#echofirst + #RHC in HFpEF and PVD by Claudia Baratto

Jean-Luc Vachiery 🫀 Luigi Denisa Muraru Gianfranco Parati MD, FESC
Istituto Auxologico Italiano

#ISHLT2024
#thepeoplesventricle

We are very pleased to announce that Ludovica Di Venanzio has joined the Paneni Lab as Research Assistant. Welcome on board Ludovica!🔬📚CTEC - Zurich University Heart Center Francesco Paneni Dept. of Cardiology - University Hospital Zurich University of Zurich Era Gorica Shafeeq mohammed Università di Pisa #HFpEF

🤔 Which is the impact of natriuretic peptide monitoring in the post-discharge management of patients with #HFpEF ? 👇

🆕Glad to share our hcontribution with the NICE randomized clinical trial, led by Domingo Pascual-Figal CIBERCV

#FreeAccess #CardioEd #CardioTwitter

We are very pleased to announce that Natalia Atzemian has joined the Paneni Lab as PhD Student. Welcome on board Natalia!🔬📚CTEC - Zurich University Heart Center Francesco Paneni Dept. of Cardiology - University Hospital Zurich University of Zurich Era Gorica Shafeeq mohammed #HFpEF

LA strain in HFpEF by LEYLA ELIF SADE in #ACVI2024 .
A must see lecture for those “online” !!!
Konstantinos Papadopoulos Alex Felix Vladyslav Kavalerchyk 🇺🇦 Márcio Mendes Rodolfo Lustosa Luigi Rafael Modesto Nicolas Merke

Welcome to the Paneni Lab Natalia! Exciting projects ahead! #HFpEF Natalia Atzemian CTEC - Zurich University Heart Center Dept. of Cardiology - University Hospital Zurich Unispital_USZ University of Zurich #PhD #Students Era Gorica Alessia Mongelli Martin Geiger Shafeeq mohammed Ludovica Di Venanzio Shehab Anwer, MD Alessandro Mengozzi

🔴 Can an implantable loop recorder improve risk stratification and appropriate management in Brugada syndrome? #openaccess #editorial European Society of Cardiology Journals

academic.oup.com/eurheartj/arti…
#Cardiotwitter #cardiology #CardioEd #HFREF #HFpEF #hfmref #meded #medtwitter #CardioTwitter #paramedic

🟢Cause-specific ☠️ in #HF across the
EF spectrum: 👥 100 000 patients in the
🇸🇪Heart Failure Registry
👥100 584 patients
📌23% HFpEF
📌23% HFmrEF
📌53% HFrEF
📌median age 75 (66–82) 36% 🙋‍♀️

👉☠️ <5 years, most deaths were CV☠️ across all EF categories

👉☠️> 5 years, HFpEF had…

Takeaways from #ACC2024 . Late breaking trials - take home points American College of Cardiology

1. RELIEVE-HF Trial: In patients with HFrEF and HFpEF, Interatrial Shunt did not show any significant difference in the primary effectiveness endpoint, a composite of all-cause mortality, LVAD/heart…

I truly enjoyed speaking about lifestyle interventions in #HFpEF and learned from the other speakers of the ACC/HFSA Joint Session on #HFpEF diagnosis and treatments. #ACC24 #ACC2024 #HFSA Kathleen Faulkenberg Vicki Groo Maya Guglin Sheldon Litwin

#JCardiol 83(5): 330-7, 2024
🌟Review
Role of splanchnic circulation in the pathogenesis of heart failure: State-of-the-art review
Yaku H et al
Hide Yaku, MD PhD

doi.org/10.1016/j.jjcc…
Elsevier Cardiology
by A.E. K

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes (STEP-HFpEF DM) nej.md/3TPKpUC

We continue to learn which #heartfailure patients may benefit most from #atrialshunt therapy. Recent RELIEVE-HF data reinforces the importance of patient selection and suggests we are on the right path with #RESPONDERHF to confirm optimal #HFpEF patients.
us.corviamedical.com/corvias-respon…

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related HFpEF with and without diabetes, and consistency across key patient subgroups?

Read the journal scan for more: bit.ly/4aRsWlN #cvPrev #ACC24

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

thelancet.com/journals/lance…

Thank you for sharing my paper, Muthu.

Polypharmacy is associated with worse HF status and outcomes in HFpEF; therefore, sometimes this can be a mirror of greater benefits of HF drugs such as sacubitril/valsartan and SGLT2i

#EJHF #JACCHF #ARNI #SGLT2i

Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HF

Polypharmacy is very common in patients with HFpEF, and those with polypharmacy have worse clinical status and a higher rate of non-fatal and fatal outcomes

onlinelibrary.wiley.com/doi/abs/10.100…

Francisco Rios Pradeep Natarajan Hypertension A13. ⬆️The associations were the most evident for stroke and all-cause death. We hope to expand the analysis to more granular CVD phenotyping to disaggregate associations for ischemic vs. hemorrhagic stroke or HFrEF vs. HFpEF #HYPHIP Hypertension
[Figure S9]